Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1500 participants.
Also called NCT02100228
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose supportive care
- Phase
- Phase 4
- Enrolled
- 1,500 participants
- Sponsor
- Registry
-
NCT02100228 -
2014-001231-36
-
- Other papers using this trial's data
- Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Denmark, Germany, Israel, Italy, Japan, Romania, South Korea, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02100228. Randomized; no masking; primary purpose supportive care. Start 2014-07-14 (actual); primary completion 2017-02-08 (actual). Results posted on 2018-04-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
- Acronym
- EMANATE
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Parenteral heparin and/or oral Vitamin K antagonist
- Lead sponsor
- Pfizer
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct02100228- Content hash
14e1fcb104f052dafe21dd4834bf6ab716c873cb41dde35e08d9f5133f453943